Skip to main content

Advertisement

Table 3 Ongoing studies with tivantinib

From: Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

NCT Number Combination Drugs PHASES URL
NCT01755767 Drug:Tivantinib Phase 3 https://ClinicalTrials.gov/show/NCT01755767
Drug: Placebo
NCT00988741 Drug: ARQ 197 Phase 2 https://ClinicalTrials.gov/show/NCT00988741
Drug: Placebo
NCT01656265 Drug: ARQ 197 Phase 1 https://ClinicalTrials.gov/show/NCT01656265
NCT00802555 Drug: ARQ 197 Phase 1 https://ClinicalTrials.gov/show/NCT00802555
NCT00557609 Drug: ARQ 197 Phase 2 https://ClinicalTrials.gov/show/NCT00557609
NCT01575522 Other: Laboratory Biomarker Analysis Phase 2 https://ClinicalTrials.gov/show/NCT01575522
Drug: Tivantinib
NCT01395758 Drug: ARQ 197 plus erlotinib Phase 2 https://ClinicalTrials.gov/show/NCT01395758
Drug: Pemetrexed, docetaxel or gemcitabine
NCT01244191 Drug: Tivantinib Phase 3 https://ClinicalTrials.gov/show/NCT01244191
Drug: Placebo
Drug: Erlotinib
NCT01069757 Drug: ARQ 197 and Erlotinib Phase 1 https://ClinicalTrials.gov/show/NCT01069757
NCT01251796 Drug: ARQ 197 and Erlotinib Phase 1 https://ClinicalTrials.gov/show/NCT01251796
NCT00777309 Drug: ARQ 197 Phase 2 https://ClinicalTrials.gov/show/NCT00777309
Drug: Erlotinib
Drug: Placebo